ArticleFrontiers in oncology2024

Long-term follow-up of combination therapy with pembrolizumab and anlotinib in thoracic SMARCA4-deficient undifferentiated tumor: a case report and molecular features.

Ting Duan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.